Encoded Therapeutics
Home
Our Science
⟵
⟵ Back
Overview
Genetic Medicines Product Engine
Pipeline & Programs
⟵
⟵ Back
Overview
Pipeline
Clinical Studies
ETX101 for Dravet Syndrome
Research Areas
Publications & Presentations
Patient
Community
⟵
⟵ Back
Overview
Patient Community Stories
Dravet Syndrome
Pre-Approval Access Statement
Healthcare
Professionals
About
News
⟵
⟵ Back
Overview
Press Releases
Media Kit
Careers
Contact
Encoded Therapeutics
News
Careers
Contact
Home
Our Science
Overview
Genetic Medicines Product Engine
Pipeline &
Programs
Overview
Pipeline
Clinical Studies
ETX101 for Dravet Syndrome
Research Areas
Publications & Presentations
Patient
Community
Overview
Patient Community Stories
Dravet Syndrome
Pre-Approval Access Statement
Healthcare
Professionals
About
Overview
Leadership
Board of Directors
Investors
A Vectorized miRNA-based Approach to Unsilence UBE3A in Angelman Syndrome
Post navigation
Previous:
ETX101: A potential one-time, disease-modifying gene regulation therapy targeting the underlying cause of
SCN1A
+ Dravet syndrome
Next:
ETX201: An experimental vectorized miRNA-based approach for the treatment of Angelman syndrome
